UPDATE 1-Roche's Herceptin gets Europe OK for breast cancer
(Adds more details)
ZURICH, May 3 (Reuters) - Swiss drugmaker Roche Holding AG (ROG.VX) said on Thursday its Herceptin had been approved in Europe for the treatment of advanced breast cancer in combination with hormonal therapy.
Herceptin was approved for the treatment of postmenopausal patients with HER2 and hormone receptor co-positive metastatic breast cancer, Roche said in a statement.
Herceptin, given by injection, is an antibody-based drug designed to target tumour cells and spare normal cells, unlike chemotherapy, which is toxic throughout the body.
The approval is based on data from an international late stage clinical trial, which showed the addition of Herceptin to hormonal therapy doubled the median progression-free survival time.
Herceptin is already approved in Europe for the treatment of early and metastatic, or advanced, HER2-positive breast cancer.
The new approval means its use can be extended, in combination with hormonal therapy for advanced breast cancer.
((Reporting by Sam Cage, editing by Sue Thomas;
Email: zurich.newsroom@reuters.com
Reuters Messaging:
sam.cage.reuters.com@reuters.net
Telephone: +41 (0) 44 631 7457)) Keywords: ROCHE HERCEPTIN/
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nL03272712
